Biodexa Pharmaceuticals PLC reported unaudited interim results for the six months ended June 30, 2026. R&D costs rose 75% to £2.92 million due to increased activity in the Serenta Phase 3 trial and manufacturing of the newly in-licensed MTX240 program. Administrative expenses decreased by 27% to £1.74 million, primarily driven by foreign exchange movements. The company incurred a net loss of £1.84 million, with finance income including a £2.38 million gain on equity-settled derivative liabilities. Cash balances fell to £3.23 million at June 30, 2026. Post-period, the company raised $3.5 million in gross proceeds through a direct offering and PIPE transaction completed on July 1, 2026. The filing highlights material uncertainties regarding going concern status due to anticipated funding needs in Q4 2026. Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company developing innovative products for gastrointestinal cancers.
